Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
26. |
ECCT/19/04/01 | A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants. Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants |
Principal Investigator(s) 1. Mainga Hamaluba 2. Kosgei Josphat Site(s) in Kenya 1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county) 2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county) |
View |
27. |
ECCT/19/08/01 | Use of malaria infection by injection to study malaria transmission Safety and feasibility of a malaria transmission model in semi-immune Kenyan adults using Plasmodium falciparum sporozoites |
Principal Investigator(s) 1. Melissa Kapulu 2. Philip Bejon Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
28. |
ECCT/23/04/02 | Shigella 53G study in Kenya Safety and feasibility of a Shigella sonnei 53G controlled human infection model in Kenyan adults: a dose finding and dose verification study |
Principal Investigator(s) 1. Melissa Kapulu 2. Fredrick Sawe Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya. |
View |
29. |
ECCT/22/05/03 | Anti-malaria MAb in Kenyan chi Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in an Age De-Escalation, Dose-Escalation Trial and a Randomized, Placebo-Controlled, Double-Blind Trial of Children in Western Kenya |
Principal Investigator(s) 1. Titus Kwambai 2. Laura Steinhardt 3. Robert A Seder Site(s) in Kenya 1. Siaya County Referral Hospital (Siaya county) 2. Kogelo Health Center (Siaya county) |
View |
30. |
ECCT/16/12/02 | Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial. |
Principal Investigator(s) 1. ISAAC TSIKHUTSU Site(s) in Kenya KEMRI/WRP, KERICHO |
View |